Compare iShares MSCI Canada (TSX) (EWC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Repligen Corporation Common Stock — how do they compare? iShares MSCI Canada (TSX) trades at $59.18 (market cap $7.17B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and iShares MSCI Canada (TSX) is more actively traded (3,409,217 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 57 Days and Repligen Corporation Common Stock for 0 Days on average.
| EWC | RGEN | |
|---|---|---|
Market Cap | $7.17B | $11.14B |
Volume | 3,409,217 | 1,259,263 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $194.57 |
52-Week Low | $49.72 | $102.87 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $59.91, up 0.77% today, with a bullish technical signal from moving averages but neutral oscillators. The stock faces support at $59 and resistance at $60. Recent news highlights Canada's trade tensions with the U.S. and potential EU associate membership, impacting market sentiment.
Outlook is clouded by trade policy uncertainty, though diversification efforts with India and Europe offer growth avenues. Key risks include U.S. tariff escalations and economic volatility. Analyst sentiment is mixed, balancing geopolitical headwinds against strategic partnerships.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
